Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation.
We examined whether melatonin exerts a therapeutic effect on cholestatic liver injury in rats treated with bile duct ligation (BDL). Cholestatic liver injury was induced in male Wistar rats aged 4 wk by ligating the bile duct. Cholestatic liver injury developed 5 days after BDL and continued to 13 days, judging from the levels of serum hepatobiliary injury markers. The serum concentration of thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation, and the hepatic level of TBARS and the activity of hepatic myeloperoxidase, an index of tissue neutrophil infiltration, increased 5 days after BDL, and these increases were enhanced at 13 days. A similar increase in the serum total cholesterol concentration occurred 5 and 13 days after BDL, while the hepatic cholesterol concentration tended to increase at 13 days. When melatonin [10 or 100 mg/kg body weight (BW)] was orally administered to BDL-treated rats everyday for 8 days, starting 5 days after BDL, the indoleamine attenuated cholestatic liver injury observed at 13 days after BDL was more effective at the higher dose than at the lower dose. The administered melatonin (10 or 100 mg/kg BW) reduced the increases in serum and hepatic TBARS concentrations and hepatic myeloperoxidase activity observed at 13 days after BDL and the higher dose of indoleamine was more effective than the lower dose. Neither dose of melatonin affected the increased serum total cholesterol concentration or the hepatic cholesterol concentration observed at 13 days after BDL. These results indicate that orally administered melatonin at pharmacological doses exerts a therapeutic effect on cholestatic liver injury in rats with BDL possibly through its antioxidant and anti-inflammatory actions.
Ohta
Yoshiji
Y
Department of Chemistry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan. yohta@fujita-hu.ac.jp
Kongo
Mutsumi
M
Kishikawa
Teruaki
T
D000818:Animals; D001652:Bile Ducts / Q000473:pathology*; D002779:Cholestasis / Q000188:drug therapy* / Q000378:metabolism; D015227:Lipid Peroxidation; D008099:Liver / Q000473:pathology*; D008297:Male; D008550:Melatonin / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances
D017392:Thiobarbituric Acid Reactive Substances; D008550:Melatonin